SKIM names Maura Coracini as Managing Director, Latin America
SKIM has named Maura Coracini as Managing Director, Latin America. Based in the São Paulo area.
Of all recent developments in the pharmaceutical industry, only few have provoked such controversy and commotion as biosimilars.
Since the introduction of the first biosimilar Omnitrope in 2006, 20 more biosimilars have been launched in Europe challenging the original brands at lower cost in various diseases. Especially the recent breakthrough entry of biosimilar monoclonal antibodies have brought a new level of complexity, making it a much tougher environment for biologics originators. It’s no longer just about lowering costs.
In this 30-minute webinar we presented our views on how marketing research and analytics can help forecast and impact the uptake of biosimilars in your different market situations. We put these views into practice by sharing learnings and challenges from a recent uptake study in the area of rheumatology among physicians and pharmacists.
Presented by: Adriënne Hoevers – den Hollander, Senior Research Manager
What you learn in this webinar
At SKIM we have learned from studies over the past few years, that not only lower costs but also many complex factors need to be considered in order to determine future impact of biosimilars. Understanding how these factors will influence uptake and how this may evolve over time will be essential for originator companies to build effective strategies across therapy areas, settings, and countries.
In this webinar you will learn about:
- Biosimilars in the past 10 years and expectations for the coming 10 years
- Drivers of biosimilar prescription beyond costs
- Influencers on biosimilar uptake
- Key Opinion Leaders’ (KOL) perspective on biosimilars and originator products
- Case study: Forecasting to measure uptake of biosimilars
